ArticleCureus2025
Safety of Recombinant Thrombomodulin for Severe Gastroenterological Sepsis-Induced Coagulopathy in Patients Undergoing Invasive Digestive Procedures: A Single-Center Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Several studies demonstrated that anticoagulant treatment, including the administration of recombinant human soluble thrombomodulin (rTM), could improve the outcomes of patients with gastroenterological sepsis-induced disseminated intravascular coagulation (DIC). However, there is little evidence on the safety of rTM administration for septic DIC requiring invasive procedures (IPs). In the current study, we assessed the safety and efficacy of rTM in patients with sepsis-induced DIC associated with digestive diseases. Methods The current retrospective cohort study included 155 cases in which rTM was administered for septic DIC associated with digestive diseases at our hospital between 2014 and 2023. The subjects were divided into an IP group (n = 102) and a non-IP group (n = 53), and background factors, the presence or absence of rTM-related complications, and mortality were compared between the groups. Results CHADS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.